Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Subjects

NCT05965570 is registered in ClinicalTrials.gov with Insmed Incorporated as lead sponsor.

NCT NCT05965570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05965570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Subjects
Lead sponsor
Insmed Incorporated
Phase
Phase 1
Overall status
Completed
Start date
July 28, 2023
Completion date
September 22, 2023
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers